The Regenerative Medicine (RM) Industry is a rapidly growing market with more than 1,550+ companies worldwide developing products for therapeutic for use in humans. As with any growing industry, the question becomes, how do you define the Regenerative Medicine Industry?
To answer this question, it is important to look at the key components that compose the human body, which are:
- Genes
- Cells
- Tissues
- Organs
Gene therapy is the use of genetic material to change the expression of a gene product, while cell therapies utilize living cells to create either direct or indirect effects within the human body. Often, technologies capable of restoring tissues and organs leverage cell and gene therapies, because tissues and organs are composed of differentiated cell types.
However, there are technologies that can directly impact the restoration of tissues and organs, such as the use of biomaterials, tissue engineering, and 3D bioprinting.
BioInformant defines Regenerative Medicine (RM) as technologies that can alter human genetic, cellular, tissue or organ function. Companies developing these technologies compose the Regenerative Medicine (RM) Industry.
Regenerative Medicine Industry Categories
The following technologies can impact genetic, cellular, tissue and/or organ function:
- Gene therapies
- Cellular therapies
- Cellular immunotherapies (CAR-T, CAR-NK, etc.)
- Stem cell therapies
- Therapeutics utilizing differentiated cell types
- Direct cell reprogramming
- Exosome therapeutics
- Tissue engineering
- Biomaterials
- 3D bioprinting
Global Regenerative Medicine Industry Database
In recent months, BioInformant’s team of analysts has updated our global database of companies developing regenerative medicine (RM) therapeutics for 2024. Composed of 1,550+ companies, it was created by our team of research analysts utilizing:
- Google Search / Google News
- Press Releases (Google Alerts)
- Funding Announcements (Crunchbase)
- ClinicalTrials.gov
- U.S. Patent and Trademark Office (USPTO) & World Intellectual Property Organization (WIPO)
- Conference Registration Lists
- LinkedIn Groups
- BioInformant’s Client & Partners
Since its launch, we have integrated crowd-sourced feedback, as well as sourced additions from our social media audiences who follow us for stem cell industry news.